A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 880
Last updated 2026-05-01
Summary
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Conditions
Interventions
- DRUG
-
Administered intravenously (IV) on Day 1 of each 21-day cycle
- DRUG
-
Administered intravenously (IV) on Day 1 of each 21-day cycle
- DRUG
-
Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
- DRUG
-
Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
- DRUG
-
Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-18
- Primary Completion
- 2029-02-05
- Completion
- 2029-10-08
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Canada
- China
- France
- Germany
- Hungary
- India
- Italy
- Japan
- Malaysia
- Netherlands
- Peru
- Poland
- Puerto Rico
- South Korea
- Spain
- Taiwan
- Thailand
- Turkey (Türkiye)
- United Kingdom
- Vietnam
Study Locations
More Related Trials
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT04623775 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
NCT01496742 ·Status: COMPLETED ·Phase: PHASE2
-
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT03132532 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05741021 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
NCT05775289 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
NCT04856176 ·Status: TERMINATED ·Phase: PHASE2
-
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
NCT04153734 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02367781 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02453282 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
NCT02621398 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
NCT04297605 ·Status: RECRUITING ·Phase: PHASE1
-
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
NCT01809210 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02366143 ·Status: COMPLETED ·Phase: PHASE3
-
Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer
NCT00016315 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
NCT07318883 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
NCT03976323 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
NCT04696939 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
NCT01519804 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer
NCT00789373 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00040794 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06236438 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
NCT00979212 ·Status: COMPLETED ·Phase: PHASE2